Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer

SIMPLE SUMMARY: There are limited treatment options beyond chemotherapy for patients with hormone receptor positive metastatic breast cancer after progression on first line therapy with CDK4/6 inhibitors and endocrine therapy. Recently, encouraging evidence has emerged from multiple drugs in this sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittal, Abhenil, Molto Valiente, Consolacion, Tamimi, Faris, Schlam, Ilana, Sammons, Sarah, Tolaney, Sara M., Tarantino, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093251/
https://www.ncbi.nlm.nih.gov/pubmed/37046675
http://dx.doi.org/10.3390/cancers15072015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093251/
https://www.ncbi.nlm.nih.gov/pubmed/37046675
http://dx.doi.org/10.3390/cancers15072015

Ejemplares similares